Kendra Young
Concepts (320)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 28 | 2025 | 923 | 2.710 |
Why?
| | Lupus Erythematosus, Systemic | 11 | 2025 | 239 | 2.590 |
Why?
| | Genetic Predisposition to Disease | 17 | 2025 | 2365 | 1.220 |
Why?
| | Smoking | 14 | 2024 | 1472 | 1.080 |
Why?
| | Tobacco Use Disorder | 4 | 2022 | 218 | 1.000 |
Why?
| | Autoantibodies | 9 | 2025 | 1504 | 0.980 |
Why?
| | Genome-Wide Association Study | 18 | 2025 | 1407 | 0.880 |
Why?
| | Mexican Americans | 2 | 2019 | 114 | 0.880 |
Why?
| | Receptors, Complement 3d | 10 | 2010 | 142 | 0.870 |
Why?
| | Smokers | 9 | 2023 | 137 | 0.830 |
Why?
| | Bronchiectasis | 5 | 2023 | 112 | 0.820 |
Why?
| | Vitamin D | 5 | 2022 | 400 | 0.810 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2023 | 266 | 0.760 |
Why?
| | Polymorphism, Single Nucleotide | 14 | 2025 | 2147 | 0.740 |
Why?
| | Coronary Artery Disease | 5 | 2025 | 741 | 0.730 |
Why?
| | Herpesvirus 4, Human | 4 | 2019 | 176 | 0.700 |
Why?
| | Vitamin D Deficiency | 2 | 2016 | 186 | 0.700 |
Why?
| | Pulmonary Emphysema | 6 | 2025 | 275 | 0.690 |
Why?
| | Diabetes Mellitus, Type 2 | 6 | 2023 | 2584 | 0.660 |
Why?
| | Spirometry | 11 | 2025 | 231 | 0.640 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 68 | 0.630 |
Why?
| | Alanine Transaminase | 2 | 2020 | 151 | 0.610 |
Why?
| | Aspartate Aminotransferases | 1 | 2019 | 85 | 0.590 |
Why?
| | Tomography, X-Ray Computed | 13 | 2025 | 2738 | 0.570 |
Why?
| | Family | 2 | 2014 | 679 | 0.570 |
Why?
| | Lipase | 1 | 2019 | 75 | 0.570 |
Why?
| | Inflammation Mediators | 2 | 2019 | 509 | 0.570 |
Why?
| | Arthritis, Rheumatoid | 5 | 2024 | 1169 | 0.550 |
Why?
| | Virus Attachment | 2 | 2008 | 18 | 0.550 |
Why?
| | Smoking Cessation | 1 | 2022 | 439 | 0.540 |
Why?
| | Cholesterol, HDL | 1 | 2018 | 200 | 0.540 |
Why?
| | Forced Expiratory Volume | 13 | 2025 | 449 | 0.540 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2016 | 16 | 0.490 |
Why?
| | Triglycerides | 1 | 2018 | 521 | 0.480 |
Why?
| | Membrane Proteins | 2 | 2020 | 1167 | 0.480 |
Why?
| | Middle Aged | 36 | 2025 | 35928 | 0.460 |
Why?
| | Adiposity | 2 | 2012 | 543 | 0.460 |
Why?
| | Metabolic Syndrome | 1 | 2018 | 354 | 0.440 |
Why?
| | Humans | 78 | 2025 | 144957 | 0.430 |
Why?
| | Genetic Variation | 6 | 2025 | 984 | 0.420 |
Why?
| | Atherosclerosis | 3 | 2023 | 409 | 0.410 |
Why?
| | Insulin-Secreting Cells | 1 | 2018 | 388 | 0.410 |
Why?
| | Insulin Resistance | 2 | 2018 | 1241 | 0.380 |
Why?
| | Male | 40 | 2025 | 72406 | 0.380 |
Why?
| | Viral Matrix Proteins | 4 | 2008 | 29 | 0.370 |
Why?
| | Female | 42 | 2025 | 78376 | 0.370 |
Why?
| | Joints | 1 | 2013 | 107 | 0.370 |
Why?
| | Acyltransferases | 3 | 2023 | 78 | 0.350 |
Why?
| | Hypertension | 1 | 2020 | 1264 | 0.350 |
Why?
| | Risk Factors | 20 | 2025 | 10792 | 0.350 |
Why?
| | Complement C3d | 7 | 2010 | 67 | 0.340 |
Why?
| | Emphysema | 2 | 2023 | 100 | 0.330 |
Why?
| | Sleep | 1 | 2018 | 901 | 0.330 |
Why?
| | Genetic Loci | 4 | 2022 | 261 | 0.320 |
Why?
| | Disease Progression | 6 | 2025 | 2852 | 0.310 |
Why?
| | Autoimmunity | 3 | 2022 | 927 | 0.310 |
Why?
| | Follow-Up Studies | 9 | 2025 | 5417 | 0.310 |
Why?
| | Adult | 19 | 2025 | 40506 | 0.280 |
Why?
| | Calcinosis | 1 | 2010 | 234 | 0.280 |
Why?
| | Diabetic Angiopathies | 1 | 2010 | 263 | 0.280 |
Why?
| | Prospective Studies | 11 | 2024 | 7997 | 0.270 |
Why?
| | Cardiovascular Diseases | 3 | 2025 | 2171 | 0.270 |
Why?
| | Genotype | 7 | 2024 | 1835 | 0.260 |
Why?
| | Case-Control Studies | 8 | 2025 | 3608 | 0.250 |
Why?
| | Viral Envelope Proteins | 1 | 2007 | 98 | 0.250 |
Why?
| | HLA-DR4 Antigen | 1 | 2007 | 74 | 0.250 |
Why?
| | Lung | 10 | 2025 | 4109 | 0.250 |
Why?
| | Aged | 19 | 2025 | 25947 | 0.250 |
Why?
| | Linkage Disequilibrium | 2 | 2024 | 247 | 0.240 |
Why?
| | Phenotype | 9 | 2025 | 3164 | 0.240 |
Why?
| | Rheumatoid Factor | 1 | 2007 | 175 | 0.230 |
Why?
| | Vital Capacity | 5 | 2025 | 290 | 0.230 |
Why?
| | Longitudinal Studies | 7 | 2025 | 2947 | 0.230 |
Why?
| | Glycoproteins | 1 | 2007 | 355 | 0.230 |
Why?
| | Tobacco Use | 2 | 2023 | 61 | 0.220 |
Why?
| | Genomic Structural Variation | 1 | 2025 | 13 | 0.220 |
Why?
| | Genetic Markers | 2 | 2019 | 331 | 0.220 |
Why?
| | Receptors, CCR2 | 1 | 2025 | 39 | 0.220 |
Why?
| | Population Surveillance | 2 | 2021 | 485 | 0.220 |
Why?
| | Multifactorial Inheritance | 2 | 2023 | 203 | 0.210 |
Why?
| | Vitamin D-Binding Protein | 2 | 2016 | 15 | 0.210 |
Why?
| | Alcohol Drinking | 2 | 2022 | 826 | 0.200 |
Why?
| | Cohort Studies | 7 | 2023 | 5965 | 0.200 |
Why?
| | Receptors, Calcitriol | 2 | 2016 | 55 | 0.200 |
Why?
| | Liver | 3 | 2023 | 1888 | 0.190 |
Why?
| | Plaque, Atherosclerotic | 1 | 2023 | 60 | 0.190 |
Why?
| | Tomography, Emission-Computed | 1 | 2022 | 71 | 0.190 |
Why?
| | Drug Repositioning | 1 | 2023 | 41 | 0.190 |
Why?
| | Peptides, Cyclic | 2 | 2015 | 275 | 0.190 |
Why?
| | Population Health | 1 | 2023 | 44 | 0.190 |
Why?
| | Autoimmune Diseases | 1 | 2007 | 463 | 0.190 |
Why?
| | Hyperlipidemias | 1 | 2023 | 122 | 0.180 |
Why?
| | Risk Assessment | 5 | 2019 | 3676 | 0.180 |
Why?
| | Liver Cirrhosis | 2 | 2023 | 288 | 0.180 |
Why?
| | Internationality | 1 | 2022 | 156 | 0.180 |
Why?
| | Airway Obstruction | 1 | 2024 | 162 | 0.180 |
Why?
| | Symptom Flare Up | 1 | 2021 | 37 | 0.170 |
Why?
| | Models, Genetic | 1 | 2024 | 536 | 0.170 |
Why?
| | Artificial Intelligence | 2 | 2023 | 367 | 0.170 |
Why?
| | Biomarkers | 3 | 2025 | 4275 | 0.170 |
Why?
| | Pulmonary Artery | 3 | 2024 | 1134 | 0.160 |
Why?
| | Mutagenesis, Site-Directed | 4 | 2010 | 381 | 0.160 |
Why?
| | Proteome | 1 | 2025 | 518 | 0.160 |
Why?
| | Severity of Illness Index | 4 | 2025 | 2925 | 0.160 |
Why?
| | Amino Acid Substitution | 4 | 2010 | 304 | 0.160 |
Why?
| | Muscular Atrophy | 1 | 2021 | 89 | 0.160 |
Why?
| | Linear Models | 2 | 2019 | 854 | 0.160 |
Why?
| | Respiratory Function Tests | 2 | 2019 | 547 | 0.160 |
Why?
| | Gene Frequency | 4 | 2024 | 481 | 0.150 |
Why?
| | Quantitative Trait, Heritable | 1 | 2020 | 118 | 0.150 |
Why?
| | China | 1 | 2020 | 269 | 0.150 |
Why?
| | Pulmonary Heart Disease | 1 | 2019 | 7 | 0.150 |
Why?
| | Molecular Epidemiology | 1 | 2019 | 73 | 0.150 |
Why?
| | Blood Pressure Determination | 1 | 2020 | 144 | 0.150 |
Why?
| | Alleles | 3 | 2019 | 881 | 0.150 |
Why?
| | Phospholipases A2, Calcium-Independent | 1 | 2019 | 18 | 0.150 |
Why?
| | Prevalence | 6 | 2023 | 2836 | 0.150 |
Why?
| | gamma-Glutamyltransferase | 1 | 2019 | 42 | 0.150 |
Why?
| | Transcriptome | 2 | 2023 | 1046 | 0.150 |
Why?
| | Prognosis | 4 | 2024 | 4293 | 0.150 |
Why?
| | Nuclear Family | 1 | 2019 | 52 | 0.150 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2020 | 3890 | 0.140 |
Why?
| | Binding Sites | 5 | 2010 | 1331 | 0.140 |
Why?
| | Atrial Fibrillation | 1 | 2025 | 550 | 0.140 |
Why?
| | Whole Genome Sequencing | 3 | 2025 | 183 | 0.140 |
Why?
| | Antigens, Viral | 1 | 2019 | 182 | 0.140 |
Why?
| | Hepatitis C | 2 | 2011 | 254 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1195 | 0.140 |
Why?
| | Heart Ventricles | 2 | 2020 | 760 | 0.140 |
Why?
| | Dyspnea | 3 | 2025 | 251 | 0.140 |
Why?
| | Herpesviridae Infections | 1 | 2019 | 150 | 0.140 |
Why?
| | Protein Binding | 7 | 2010 | 2276 | 0.130 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 1 | 2017 | 37 | 0.130 |
Why?
| | Blood Pressure | 2 | 2023 | 1769 | 0.130 |
Why?
| | Vascular Remodeling | 1 | 2019 | 205 | 0.130 |
Why?
| | Protein Structure, Tertiary | 3 | 2008 | 862 | 0.120 |
Why?
| | Coronary Vessels | 1 | 2018 | 251 | 0.120 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2016 | 18 | 0.120 |
Why?
| | Lung Diseases | 1 | 2023 | 787 | 0.120 |
Why?
| | Crystallography, X-Ray | 6 | 2010 | 493 | 0.120 |
Why?
| | Complement C3b | 3 | 2007 | 30 | 0.120 |
Why?
| | United States | 5 | 2020 | 15988 | 0.120 |
Why?
| | Mutation, Missense | 2 | 2008 | 340 | 0.120 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 80 | 0.120 |
Why?
| | Fatigue | 1 | 2018 | 366 | 0.120 |
Why?
| | Lipids | 1 | 2020 | 710 | 0.110 |
Why?
| | Body Mass Index | 3 | 2021 | 2438 | 0.110 |
Why?
| | Antibodies, Viral | 1 | 2019 | 672 | 0.110 |
Why?
| | Abdominal Fat | 2 | 2017 | 50 | 0.100 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 142 | 0.100 |
Why?
| | Antibodies, Antinuclear | 1 | 2014 | 62 | 0.100 |
Why?
| | Multivariate Analysis | 3 | 2019 | 1540 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 851 | 0.100 |
Why?
| | Machine Learning | 1 | 2019 | 587 | 0.100 |
Why?
| | Europe | 3 | 2022 | 412 | 0.100 |
Why?
| | Fluorescent Antibody Technique | 1 | 2014 | 370 | 0.100 |
Why?
| | Calcium | 1 | 2018 | 1184 | 0.090 |
Why?
| | Quality of Life | 2 | 2025 | 3192 | 0.090 |
Why?
| | Hyperglycemia | 1 | 2016 | 375 | 0.090 |
Why?
| | Family Health | 1 | 2013 | 191 | 0.090 |
Why?
| | Recombinant Proteins | 5 | 2007 | 1371 | 0.090 |
Why?
| | Sample Size | 2 | 2022 | 123 | 0.090 |
Why?
| | Models, Molecular | 6 | 2008 | 1619 | 0.090 |
Why?
| | Peptide Fragments | 3 | 2007 | 699 | 0.090 |
Why?
| | Mutant Proteins | 2 | 2010 | 106 | 0.090 |
Why?
| | Cross-Sectional Studies | 4 | 2024 | 5872 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2019 | 1325 | 0.080 |
Why?
| | Texas | 1 | 2012 | 278 | 0.080 |
Why?
| | Protein Interaction Mapping | 2 | 2008 | 105 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1980 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 529 | 0.080 |
Why?
| | Patient Care Team | 1 | 2016 | 689 | 0.080 |
Why?
| | Antibodies, Monoclonal | 4 | 2007 | 1524 | 0.080 |
Why?
| | K562 Cells | 2 | 2007 | 93 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2118 | 0.080 |
Why?
| | Epidemics | 1 | 2011 | 98 | 0.080 |
Why?
| | Registries | 1 | 2019 | 2385 | 0.080 |
Why?
| | Life Style | 1 | 2012 | 479 | 0.070 |
Why?
| | Intra-Abdominal Fat | 1 | 2009 | 100 | 0.070 |
Why?
| | Depression | 1 | 2018 | 1559 | 0.070 |
Why?
| | Regression Analysis | 2 | 2022 | 1003 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2010 | 612 | 0.070 |
Why?
| | Sex Factors | 2 | 2020 | 2114 | 0.070 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2008 | 148 | 0.070 |
Why?
| | Meta-Analysis as Topic | 2 | 2020 | 174 | 0.070 |
Why?
| | Bronchodilator Agents | 2 | 2021 | 183 | 0.070 |
Why?
| | Point Mutation | 1 | 2008 | 243 | 0.070 |
Why?
| | Exercise Tolerance | 2 | 2020 | 283 | 0.070 |
Why?
| | Retrospective Studies | 3 | 2021 | 17101 | 0.070 |
Why?
| | Bottle Feeding | 1 | 2007 | 19 | 0.060 |
Why?
| | Histocompatibility Testing | 1 | 2007 | 121 | 0.060 |
Why?
| | Insulin | 1 | 2017 | 2507 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 6053 | 0.060 |
Why?
| | Health Behavior | 1 | 2012 | 786 | 0.060 |
Why?
| | Hospitalization | 1 | 2016 | 2434 | 0.060 |
Why?
| | Bronchitis, Chronic | 1 | 2025 | 16 | 0.060 |
Why?
| | Interferon-alpha | 1 | 2006 | 197 | 0.060 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2025 | 46 | 0.050 |
Why?
| | Chemokine CCL2 | 1 | 2025 | 116 | 0.050 |
Why?
| | Tobacco Smoke Pollution | 1 | 2007 | 233 | 0.050 |
Why?
| | Phospholipases | 1 | 2023 | 14 | 0.050 |
Why?
| | Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2023 | 27 | 0.050 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2023 | 75 | 0.050 |
Why?
| | United Kingdom | 1 | 2024 | 338 | 0.050 |
Why?
| | Multimorbidity | 1 | 2023 | 63 | 0.050 |
Why?
| | Pandemics | 1 | 2011 | 1695 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2024 | 282 | 0.050 |
Why?
| | Computer Simulation | 2 | 2024 | 1026 | 0.040 |
Why?
| | Monocytes | 1 | 2025 | 538 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2007 | 877 | 0.040 |
Why?
| | Biology | 1 | 2023 | 91 | 0.040 |
Why?
| | Pectoralis Muscles | 1 | 2021 | 17 | 0.040 |
Why?
| | Reference Values | 1 | 2023 | 798 | 0.040 |
Why?
| | Epitope Mapping | 1 | 2001 | 61 | 0.040 |
Why?
| | Logistic Models | 1 | 2007 | 2119 | 0.040 |
Why?
| | Colorado | 1 | 2012 | 4564 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2019 | 8279 | 0.040 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 26 | 0.040 |
Why?
| | Bronchi | 1 | 2022 | 267 | 0.040 |
Why?
| | Vitamins | 1 | 2022 | 178 | 0.040 |
Why?
| | Ligands | 4 | 2006 | 674 | 0.040 |
Why?
| | Inheritance Patterns | 1 | 2020 | 44 | 0.040 |
Why?
| | Molecular Sequence Annotation | 1 | 2020 | 105 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2023 | 460 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2008 | 3550 | 0.040 |
Why?
| | Interleukin-10 | 1 | 2022 | 310 | 0.040 |
Why?
| | Myocytes, Cardiac | 1 | 2025 | 556 | 0.040 |
Why?
| | Models, Statistical | 1 | 2024 | 682 | 0.040 |
Why?
| | Hepacivirus | 2 | 2011 | 243 | 0.040 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 2019 | 7 | 0.040 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2019 | 9 | 0.040 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2019 | 12 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2022 | 479 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2021 | 575 | 0.040 |
Why?
| | Drug Discovery | 1 | 2020 | 155 | 0.040 |
Why?
| | Age Factors | 1 | 2007 | 3335 | 0.040 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2019 | 45 | 0.040 |
Why?
| | Surface Plasmon Resonance | 3 | 2006 | 89 | 0.040 |
Why?
| | Walk Test | 1 | 2019 | 80 | 0.040 |
Why?
| | Binding, Competitive | 3 | 2006 | 193 | 0.040 |
Why?
| | Organ Size | 1 | 2019 | 463 | 0.030 |
Why?
| | Organ Specificity | 1 | 2019 | 313 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2019 | 521 | 0.030 |
Why?
| | Genomics | 1 | 2023 | 836 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1048 | 0.030 |
Why?
| | Military Personnel | 1 | 2025 | 747 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 479 | 0.030 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 293 | 0.030 |
Why?
| | Self Report | 1 | 2022 | 873 | 0.030 |
Why?
| | Body Composition | 1 | 2021 | 706 | 0.030 |
Why?
| | Environment | 1 | 2019 | 305 | 0.030 |
Why?
| | Chronic Disease | 1 | 2023 | 1813 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 339 | 0.030 |
Why?
| | Mortality | 1 | 2019 | 376 | 0.030 |
Why?
| | Incidence | 2 | 2015 | 2883 | 0.030 |
Why?
| | Risk | 1 | 2019 | 911 | 0.030 |
Why?
| | Cause of Death | 1 | 2018 | 472 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 966 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2017 | 361 | 0.030 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2015 | 25 | 0.030 |
Why?
| | Chromosomes, Human, Pair 15 | 1 | 2015 | 50 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2017 | 374 | 0.030 |
Why?
| | Amino Acid Sequence | 3 | 2006 | 2157 | 0.030 |
Why?
| | Receptors, IgE | 2 | 2006 | 43 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2006 | 2931 | 0.030 |
Why?
| | Repetitive Sequences, Amino Acid | 2 | 2005 | 19 | 0.020 |
Why?
| | Genome, Human | 1 | 2015 | 422 | 0.020 |
Why?
| | Mutagenesis | 2 | 2006 | 192 | 0.020 |
Why?
| | Solutions | 2 | 2005 | 167 | 0.020 |
Why?
| | Egypt | 1 | 2011 | 13 | 0.020 |
Why?
| | Child, Preschool | 1 | 2007 | 11799 | 0.020 |
Why?
| | Israel | 1 | 2011 | 46 | 0.020 |
Why?
| | Asia | 1 | 2011 | 70 | 0.020 |
Why?
| | Consensus Sequence | 2 | 2001 | 74 | 0.020 |
Why?
| | Protein Conformation | 2 | 2006 | 946 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2880 | 0.020 |
Why?
| | Australia | 1 | 2011 | 286 | 0.020 |
Why?
| | Time Factors | 2 | 2011 | 7183 | 0.020 |
Why?
| | Canada | 1 | 2011 | 428 | 0.020 |
Why?
| | Young Adult | 1 | 2025 | 14126 | 0.020 |
Why?
| | Molecular Dynamics Simulation | 1 | 2010 | 260 | 0.020 |
Why?
| | Infant | 1 | 2021 | 10039 | 0.020 |
Why?
| | Spodoptera | 1 | 2006 | 40 | 0.020 |
Why?
| | Child | 1 | 2007 | 22657 | 0.020 |
Why?
| | Myxovirus Resistance Proteins | 1 | 2006 | 13 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2006 | 76 | 0.020 |
Why?
| | HSP40 Heat-Shock Proteins | 1 | 2006 | 26 | 0.020 |
Why?
| | Polysaccharides | 1 | 2006 | 87 | 0.010 |
Why?
| | Glycosylation | 1 | 2006 | 172 | 0.010 |
Why?
| | GTP-Binding Proteins | 1 | 2006 | 153 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2006 | 142 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 561 | 0.010 |
Why?
| | Protein Structure, Quaternary | 1 | 2005 | 116 | 0.010 |
Why?
| | Static Electricity | 1 | 2005 | 113 | 0.010 |
Why?
| | Dimerization | 1 | 2005 | 194 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2006 | 496 | 0.010 |
Why?
| | Multiprotein Complexes | 1 | 2005 | 172 | 0.010 |
Why?
| | Animals | 4 | 2010 | 38109 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1048 | 0.010 |
Why?
| | Neutrons | 1 | 2002 | 10 | 0.010 |
Why?
| | Scattering, Radiation | 1 | 2002 | 103 | 0.010 |
Why?
| | Antigen-Antibody Complex | 1 | 2001 | 72 | 0.010 |
Why?
| | Protein Sorting Signals | 1 | 2001 | 20 | 0.010 |
Why?
| | Pichia | 1 | 2001 | 19 | 0.010 |
Why?
| | Ultracentrifugation | 1 | 2001 | 51 | 0.010 |
Why?
| | Hydrogen Bonding | 1 | 2001 | 169 | 0.010 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2001 | 143 | 0.010 |
Why?
| | Cell Line | 1 | 2006 | 2882 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2001 | 368 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 2001 | 369 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2001 | 541 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2001 | 570 | 0.010 |
Why?
| | Protein Folding | 1 | 2001 | 279 | 0.010 |
Why?
| | Complement Activation | 1 | 2002 | 411 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2006 | 4155 | 0.010 |
Why?
| | HIV-1 | 1 | 2001 | 896 | 0.010 |
Why?
| | Models, Biological | 1 | 2002 | 1822 | 0.010 |
Why?
| | Mice | 2 | 2002 | 18365 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2001 | 3125 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2001 | 1982 | 0.010 |
Why?
|
|
Young's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|